149 results on '"de Pouvourville, Gérard"'
Search Results
2. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)
3. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France
4. A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial
5. Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union’s Regulation on Health Technology Assessment for Vaccines
6. Population norms in France with EQ-5D-5L: health states, value indexes, and VAS
7. Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective
8. Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
9. Les cellules CAR-T : prix, efficience et soutenabilité en France
10. Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study
11. The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation
12. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making
13. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers
14. Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
15. The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed
16. Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?
17. Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?
18. Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France
19. Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France.
20. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France
21. Value of a QALY for France: A New Approach to Propose Acceptable Reference Values
22. A French Value Set for the EQ-5D-5L
23. Generalized pustular psoriasis: A nationwide population‐based study using the National Health Data System in France.
24. Costs associated with community acquired pneumonia in France
25. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
26. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers
27. The Heterogeneity of Markets for Drugs in Europe: The Cost of Distribution
28. Hospital Funding and Competition
29. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
30. Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?
31. Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
32. Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012
33. L’évaluation médico-économique des produits de santé dans le contexte de la loi de financement de la Sécurité sociale pour 2012
34. HAS to be NICE?
35. Paying doctors for performance
36. Valuing EQ-5D using Time Trade-Off in France
37. Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France.
38. A French approach to cost-effectiveness analysis?
39. Guidelines for Completing the EURONHEED Transferability Information Checklists
40. Les hôpitaux français face au paiement prospectif au cas: La mise en œuvre de la tarification à l'activité
41. The Cost of Treating High Blood Pressure in General Practice in France
42. Risk-Sharing Agreements for Innovative Drugs: A New Solution to Old Problems?
43. Can Economic Evaluations Be Made More Transferable?
44. A review of data systems for assessing the impact of HPV vaccination in selected high-income countries.
45. Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France.
46. Treatment of wet age-related macular degeneration by ranibizumab in “real life” in France: treatment behaviours and associated visual outcome
47. Qu’est-ce qu’une unité de soins « performante », du point de vue des malades relevant de soins palliatifs et de leurs proches ?
48. Hospital Reforms in France under a Socialist Government
49. Quality of Care Initiatives in the French Context
50. Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.